Noninvasive diagnosis of moderate to severe endometriosis: the platelet-lymphocyte ratio cannot be a neoadjuvant biomarker for serum cancer antigen 125

Hua Yang,Lan Zhu,Shu Wang,Jinghe Lang,Tao Xu

DOI: https://doi.org/10.1016/j.jmig.2013.06.003

Abstract:Study objective: To investigate whether the combined value of the platelet-lymphocyte ratio (PLR) and serum cancer antigen 125 (CA 125) can be used in diagnosing moderate to severe endometriosis. Design: A retrospective study (Canadian Task Force classification II-2). Setting: A single center (Department of Obstetrics and Gynecology, Physical Examination Center of Peking Union Medical College Hospital, Beijing, China). Patients: Two hundred ninety-nine premenopausal women who underwent laparoscopic surgery, 197 patients with moderate to severe endometriosis, 102 patients with benign tumor, and 112 healthy subjects. Interventions: None. Main outcome measures: Analyses were performed using 1-way analysis of variance and receiver operating characteristic (ROC) curves. Results: The mean absolute value of serum CA 125, PLR, and the combination values were significantly increased for patients in the moderate to severe endometriosis group (p = .000, p = .004, p = .009, respectively). The area under the curve (AUC) for CA 125 was 0.943 (95% confidence interval [CI], 0.918-0.967) with a sensitivity and specificity of 71.6% and 99.1%, respectively. The AUC for PLR was 0.587 (95% CI, 0.520-0.653) with a sensitivity of 65.0%, a specificity of 51.8%, and a cutoff value at 117.16. The combination, which was calculated by multiplying CA 125 levels by the PLR, with an AUC of 0.929 (95% CI, 0.900-0.958) and a cutoff value of 2812.40, showed the highest sensitivity of 90.4% but a lower specificity of 84.8%. Conclusion: Serum CA 125 is better than the PLR and the combination biomarkers in diagnosing moderate to severe endometriosis.